-+ 0.00%
-+ 0.00%
-+ 0.00%

Hoth Therapeutics Advances Phase 2 Trial of HT-001 for EGFR-Inhibitor-Associated Rash

Reuters·12/03/2025 19:00:15

Please log in to view news